{"id":674,"date":"2019-01-07T01:58:21","date_gmt":"2019-01-07T01:58:21","guid":{"rendered":"https:\/\/staging.vantagebiotrials.com\/?p=674"},"modified":"2024-03-17T23:00:44","modified_gmt":"2024-03-17T23:00:44","slug":"vantage-biotrials-passes-health-canada-inspection","status":"publish","type":"post","link":"https:\/\/vantagebiotrials.com\/fr\/vantage-biotrials-passes-health-canada-inspection\/","title":{"rendered":"Vantage BioTrials Passes Health Canada Inspection"},"content":{"rendered":"

January 7, 2019, Montreal, Canada <\/strong>– Earlier this year, Vantage BioTrials (VBT) took a very important step forward by volunteering to take part in the first of its kind Health Canada pilot inspection program. The program focused on VBT’s internal processes, procedures & protocol specific studies.<\/p>\n

\n

“Through our dedication & transparency for adhering to quality principles, we continue to add tangible credibility towards achieving operational excellence for our clients, patient groups & partners”<\/em><\/h3>\n

Vatche Bartekian, President<\/p>\n<\/blockquote>\n

Vantage BioTrials was one of two Clinical Trial Management CRO’s chosen by Health Canada in 2018. “Even though their pilot inspection program will be extended into 2019, it is a major accomplishment for us (VBT) to have set a marker for other companies to follow. Through our compliance, we demonstrated\u00a0that our processes, procedures, Corrective Action\/Preventive Action (CAPA<\/strong>), Risk-based Monitoring<\/strong> & Risk-based Trial Management <\/strong>approaches are sound.” adds Vahe Bartekian, Vice-President of Quality Management.<\/p>\n

Vantage BioTrials looks forward to the years ahead by continuing to add value to the Phase I-IV & medical device clinical development needs of its clients, patient groups & partners.<\/p>\n

About us<\/strong><\/h3>\n

Founded in 2007, Vantage BioTrials is a privately-held Contract Research Organization (CRO) that provides Phase I-IV clinical trial management services and implements Risk-Based Management through the use of Quality by Design (QbD) methodologies, all delivered to international pharmaceutical, biotechnology, generic pharmaceutical and medical device companies.<\/p>\n

Follow us on\u00a0LinkedIn<\/a>\u00a0and\u00a0Twitter<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"

January 7, 2019, Montreal, Canada – Earlier this year, Vantage BioTrials (VBT) took a very important step forward by volunteering to take part in the first of its kind Health Canada pilot inspection program. The program focused on VBT’s internal processes, procedures & protocol specific studies. “Through our dedication & transparency for adhering to quality principles, we continue to add tangible credibility towards achieving operational excellence for our clients, patient groups & partners” Vatche Bartekian, President Vantage BioTrials was one of two Clinical Trial Management CRO’s chosen by Health Canada in 2018. “Even though their pilot inspection program will be extended into 2019, it is a major accomplishment for us (VBT) to have set a marker for other companies to follow. Through our compliance, we demonstrated\u00a0that our processes, procedures, Corrective Action\/Preventive Action (CAPA), Risk-based Monitoring & Risk-based Trial Management approaches are sound.” adds Vahe Bartekian, Vice-President of Quality Management. Vantage BioTrials looks forward to the years ahead by continuing to add value to the Phase I-IV & medical device clinical development needs of its clients, patient groups & partners. About us Founded in 2007, Vantage BioTrials is a privately-held Contract Research Organization (CRO) that provides Phase I-IV clinical trial management services and implements Risk-Based Management through the use of Quality by Design (QbD) methodologies, all delivered to international pharmaceutical, biotechnology, generic pharmaceutical and medical device companies. Follow us on\u00a0LinkedIn\u00a0and\u00a0Twitter.<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[20],"tags":[],"class_list":["post-674","post","type-post","status-publish","format-standard","hentry","category-news-pressroom","cms-no-post-thumbnail"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/posts\/674","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/comments?post=674"}],"version-history":[{"count":0,"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/posts\/674\/revisions"}],"wp:attachment":[{"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/media?parent=674"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/categories?post=674"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/tags?post=674"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}